Miriam Y. Kim, M.D. joined the Department of Medicine as an Instructor in the Division of Oncology on August 15, 2017.
Dr. Kim completed her clinical fellowship in Hematology and Oncology at the University of Southern California and then did postdoctoral research at the University of Pennsylvania. Her primary interest is developing immunotherapy for the treatment of myeloid malignancies. To this end, she is working on developing chimeric antigen receptor T cells (CART cells) for the treatment of acute myeloid leukemia (AML). Due to the paucity of appropriate cell surface antigens to target in AML, her work has focused on using gene editing to make normal hematopoietic stem cells resistant to CART cells, so that the CART cells can safely eliminate leukemia without prolonged toxicity to the normal hematopoetic system.